Table 4.

The adverse events, patient compliance and costs of each therapy group.

	VA (n = 78), % (n/N)	VBQT (n = 78), % (n/N)	P value
No. of patients with adverse event	10.3 (8/78)	17.9 (14/78)	.250
Diarrhoea	6.4 (5/78)	5.1 (4/78)	1.000
Abdominal bloating	1.3 (1/78)	1.3 (1/78)	1.000
Nausea	2.6 (2/78)	2.6 (2/78)	1.000
Abdominal discomfort	0 (0/78)	1.3 (1/78)	1.000
Skin rash	0 (0/78)	1.3 (1/78)	1.000
Bitter mouth	0 (0/78)	2.6 (2/78)	.497
Anorexia	0 (0/78)	1.3 (1/78)	1.000
Itching	0 (0/78)	1.3 (1/78)	1.000
Giddy	0 (0/78)	1.3 (1/78)	1.000
Total no. of adverse events	8	14
Mild	8	13
Moderate	0	1
Severe	0	0
Compliance	96.2 (75/78)	96.2 (75/78)	1.000
Costs (yuan)	348.6	532.7

Chi-square and Fisher’s exact tests was used for statistical analysis. All results were considered significant if the P value was < .05.

VA = vonoprazan–amoxicillin dual therapy, VBQT = vonoprazan-based bismuth-containing quadruple therapy.